<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018365</url>
  </required_header>
  <id_info>
    <org_study_id>190012</org_study_id>
    <nct_id>NCT04018365</nct_id>
  </id_info>
  <brief_title>A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance</brief_title>
  <acronym>EMPIRE-01</acronym>
  <official_title>A Multicenter, Open-label, Single-arm Study With Regard to the Efficacy and Safety of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kobe University</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kobe University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, open-label, single-arm study with regard to the efficacy and safety of
      empagliflozin in patients with refractory diabetes mellitus with insulin resistance
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the clinical efficacy of a treatment with empagliflozin in refractory diabetes
      mellitus patients with insulin resistance (insulin resistance syndrome, lipoatrophic diabetes
      mellitus) by using the HbA1c change at Week 24 of treatment from baseline
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change at Week 24 of the treatment from baseline</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>With regard to the HbA1c change at Week 24 of the treatment from baseline, changes will be shown by patient, as well as summarizing with the size of sample, mean, standard deviation, minimum, median, and maximum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c change rate at Week 24 of the treatment from baseline</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>With regard to the HbA1c change rate at Week 24 of the treatment from baseline, change rates will be shown by patient, as well as summarizing with the size of sample, mean, standard deviation, minimum, median, and maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c change at Week 12 of the treatment from baseline</measure>
    <time_frame>at Week 12 of the treatment from baseline</time_frame>
    <description>With regard to the HbA1c change at Week 12 of the treatment from baseline, changes will be shown by patient, as well as summarizing with the size of sample, mean, standard deviation, minimum, median, and maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c over time</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>The HbA1c level at measurement time point is tabulated by patient, as well as plotting the HbA1c level over time by line graph. In addition, the mean, standard deviation, interquartile range, minimum, median, and maximum of HbA1c at each time point will be calculated and tabulated, as well as displaying the mean at each measurement time point with error bar of standard deviation by line graph.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose (FPG) over time</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>The FPG level at measurement time point is tabulated by patient, as well as plotting the FPG level over time by line graph. In addition, the mean, standard deviation, interquartile range, minimum, median, and maximum of FPG at each time point will be calculated and tabulated, as well as displaying the mean at each measurement time point with error bar of standard deviation by line graph.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG change at Week 24 of the treatment from baseline</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>With regard to the FPG change at Week 24 of the treatment from baseline, changes will be shown by patient, as well as summarizing with the size of sample, mean, standard deviation, minimum, median, and maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of insulin dose</measure>
    <time_frame>at Week 24 of the treatment from baseline</time_frame>
    <description>The insulin dose of each patient will be tabulated by time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glucose for 2 hours over time</measure>
    <time_frame>2 Weeks from Day0 and Day140</time_frame>
    <description>The postprandial glucose for 2 hours at measurement time point is tabulated by patient, and the glucose level over time is plotted by line graph. In addition, the mean, standard deviation, interquartile range, minimum, median, and maximum of postprandial glucose for 2 hours at each time point will be tabulated, and the mean at each measurement time point with an error bar of standard deviation will be displayed by line graph.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Insulin Resistance - Type A</condition>
  <condition>Insulin Resistance - Type B</condition>
  <condition>Lipoatrophic Diabetes Mellitus</condition>
  <condition>Insulin Resistance Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment of empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin 10 mg is to be continuously administered once daily for 12 weeks. Measure an HbA1c level after 12 weeks and determine the dose (Week 13 to Week 24). In case of &lt;7.0%, 10 mg will be continued: in case of &gt;=7.0%, it will be increased to 25 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin Tablets</intervention_name>
    <description>The administration is oral administration with water before or after breakfast.</description>
    <arm_group_label>Treatment of empagliflozin</arm_group_label>
    <other_name>BI10773</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) A patient who has been diagnosed with insulin resistance syndrome (type A, type B,
             type non-A non-B) or lipoatrophic diabetes mellitus prior to obtaining consent

          -  2) A patient who has received consistent dosage and administration of drugs aiming a
             hypoglycemic effect and consistent instructions of diet therapy/exercise therapy for
             more than 12 weeks before enrollment

          -  3) A patient with &gt;= 7.0 % of HbA1c at the time of screening

          -  4) A patient, if taking other SGLT2 inhibitor than empagliflozin, whose SGLT2
             inhibitor can be washed out for more than 12 weeks prior to starting empagliflozin

          -  5) A patient at the age of &gt;=20 years at the time of consent

          -  6) A patient who has received sufficient explanation with regard to information such
             as the objectives and details of this study, expected drug efficacy/pharmacological
             action, and risks, and has given written consent by her/himself.

        Exclusion Criteria:

          -  1) A patient with a medical history of acute coronary syndrome (including
             non-ST-elevation myocardial infarction, ST-elevation myocardial infarction, and
             unstable angina pectoris), stroke or transient ischemic attack (TIA) within 3 months
             before obtaining consent

          -  2) A patient with suspected hepatic dysfunction, that either of serum ALT, AST or
             alkaline phosphatase in the screening period is exceeding 3-fold of upper limit of
             normal rang

          -  3) A patient who is receiving a systemic steroid at the time of consent (except for
             type B)

          -  4) A patient whose thyroid hormone product dose has been changed within 6 weeks before
             obtaining consent

          -  5) A patient with unstable endocrine diseases other than diabetes mellitus

          -  6) A patient with hemolysis or blood diseases that destabilize erythrocytic cells and
             other various disorders (e.g., malaria, babesiosis, hemolytic anemia).

          -  7) A premenopausal female patient (the latest menstruation was within 1 year before
             obtaining consent), a lactating or pregnant patient, or a patient who may be pregnant
             (without hysterectomy or ovariectomy) who has no intention to use efficacious
             contraception defined in this study during the treatment period and would not agree to
             receive regular pregnancy tests during the treatment period

          -  8) A patient who has experienced alcohol abuse or drug abuse within 3 months before
             obtaining consent, which may disturb the study participation

          -  9) A patient who is in the condition that makes it difficult to administer the study
             drug

          -  10) A patient with renal dysfunction of eGFR (MDRD calculating formula) &lt; 45
             mL/min/1.73 m2 in the screening period

          -  11) A patient who indicates a hypersensitivity response to empagliflozin or its
             excipients, or a patient with lactose-intolerance

          -  12) A patient with severe ketosis, diabetic coma or precoma, severe infection,
             perioperative status, or serious trauma

          -  13) A patient that the investigator and/or subinvestigator, etc., has judged to be
             ineligible to this study for other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wataru Ogawa</last_name>
    <role>Study Chair</role>
    <affiliation>Kobe University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasumasa Kakei</last_name>
    <phone>81-78-382-5400</phone>
    <email>ctrcpj-empire@med.kobe-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hisayo Morioka</last_name>
    <phone>81-6-6202-5375</phone>
    <email>prj-empire-epcr@eps.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wataru Ogawa, Professor</last_name>
      <phone>81-78-382-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junta Imai, Associ.Prof.</last_name>
      <phone>81-22-717-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Ebihara, Associ.Prof.</last_name>
      <phone>81-285-44-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NIhon University Hospital</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatsuhiko Urakami, Professor</last_name>
      <phone>81-3-3293-1711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Wada, Professor</last_name>
      <phone>81-86-223-7151</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kobe University</investigator_affiliation>
    <investigator_full_name>Wataru Ogawa</investigator_full_name>
    <investigator_title>Professor, Division of Diabetes and Endocrinology</investigator_title>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <keyword>refractory diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy, Congenital Generalized</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus, Lipoatrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

